Third Party Agreements - Additional Information (Details) - USD ($) $ in Thousands		12 Months Ended
	Jan. 28, 2022	Dec. 31, 2023	Dec. 31, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development in process 1		$ 1,000
License agreement termination description		twelve (12) years
Payment from Regeneron for exercise of its option to license exclusive rights		$ 4	$ 1,315
Regeneron Pharmaceuticals, Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non refundable upfront payment received		25,000
Additional payment for research funding received		20,000
Exercise Fee Paid	$ 20,000	20,000
Revenue recognized		5,000
Licence agreement additional revenue recognised		25,000
Regeneron Pharmaceuticals, Inc. | Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Licence agreement additional amount payable of option exercise fees		$ 80,000